Document/ExhibitDescriptionPagesSize 1: 10-Q Quarterly Report HTML 787K
2: EX-22.2 Published Report re: Matters Submitted to a Vote HTML 24K
of Security Holders
3: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 21K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 21K
13: R1 Cover HTML 72K
14: R2 Consolidated Statements of Operations HTML 123K
15: R3 Consolidated Statements of Comprehensive Income HTML 49K
(Loss)
16: R4 Consolidated Balance Sheets HTML 119K
17: R5 Consolidated Balance Sheets (Parenthetical) HTML 33K
18: R6 Consolidated Statements of Cash Flows HTML 116K
19: R7 Consolidated Statements of Changes in Equity HTML 79K
20: R8 Consolidated Statements of Changes in Equity HTML 24K
(Parenthetical)
21: R9 Summary of Significant Accounting Policies HTML 33K
22: R10 Fair Value HTML 24K
23: R11 Discontinued Operations HTML 42K
24: R12 Goodwill and Intangible Assets HTML 48K
25: R13 Exit and Realignment Costs HTML 53K
26: R14 Debt HTML 57K
27: R15 Retirement Plans HTML 39K
28: R16 Derivatives HTML 64K
29: R17 Income Taxes HTML 26K
30: R18 Net Income (Loss) per Common Share HTML 58K
31: R19 Shareholders' Equity HTML 26K
32: R20 Accumulated Other Comprehensive Loss HTML 108K
33: R21 Segment Information HTML 100K
34: R22 Recent Accounting Pronouncements HTML 34K
35: R23 Summary of Significant Accounting Policies HTML 46K
(Policies)
36: R24 Summary of Significant Accounting Policies HTML 38K
(Tables)
37: R25 Discontinued Operations (Tables) HTML 42K
38: R26 Goodwill and Intangible Assets (Tables) HTML 49K
39: R27 Exit and Realignment Costs (Tables) HTML 53K
40: R28 Debt (Tables) HTML 46K
41: R29 Retirement Plans (Tables) HTML 34K
42: R30 Derivatives (Tables) HTML 65K
43: R31 Net Income (Loss) per Common Share (Tables) HTML 58K
44: R32 Accumulated Other Comprehensive Loss (Tables) HTML 107K
45: R33 Segment Information (Tables) HTML 100K
46: R34 Summary of Significant Accounting Policies - HTML 32K
Schedule of Cash, Cash Equivalents and Restricted
Cash (Details)
47: R35 Discontinued Operations - Narrative (Details) HTML 32K
48: R36 Discontinued Operations - Summary of Financial HTML 59K
Results of Discontinued Operations (Details)
49: R37 Discontinued Operations - Schedule of Cash Flow HTML 30K
Information for Discontinued Operations (Details)
50: R38 Goodwill and Intangible Assets - Changes in HTML 30K
Carrying Amount of Goodwill (Details)
51: R39 Goodwill and Intangible Assets - Intangible Assets HTML 37K
(Details)
52: R40 Goodwill and Intangible Assets - Narrative HTML 45K
(Details)
53: R41 Exit and Realignment Costs - Exit and realignment HTML 27K
charges by segment (Details)
54: R42 Exit and Realignment Costs - Accrual for Exit and HTML 37K
Realignment Costs (Details)
55: R43 Exit and Realignment Costs - Narrative (Details) HTML 32K
56: R44 Debt - Schedule of Debt (Details) HTML 67K
57: R45 Debt - Narrative (Details) HTML 82K
58: R46 Retirement Plans - Components of Net Periodic HTML 52K
Benefit Cost (Details)
59: R47 Derivatives - Summary of the terms and fair value HTML 44K
of our outstanding derivative financial
instruments (Details)
60: R48 Derivatives - Summary of the effect of cash flow HTML 40K
hedge (Details)
61: R49 Derivatives - Narrative (Details) HTML 30K
62: R50 Income Taxes - Narrative (Details) HTML 26K
63: R51 Net Income (Loss) per Common Share - Summary of HTML 87K
Calculation of Net Loss Per Common Share (Details)
64: R52 Shareholders' Equity - Narrative (Details) HTML 28K
65: R53 Accumulated Other Comprehensive Loss - Changes in HTML 67K
Accumulated Loss by Component (Details)
66: R54 Segment Information - Financial Information by HTML 65K
Segment (Details)
67: R55 Segment Information - Consolidated Total Assets HTML 38K
(Details)
68: R56 Segment Information - Net revenue by geographic HTML 30K
area (Details)
70: XML IDEA XML File -- Filing Summary XML 124K
12: XML XBRL Instance -- omi-20210630_htm XML 2.00M
69: EXCEL IDEA Workbook of Financial Reports XLSX 79K
8: EX-101.CAL XBRL Calculations -- omi-20210630_cal XML 182K
9: EX-101.DEF XBRL Definitions -- omi-20210630_def XML 434K
10: EX-101.LAB XBRL Labels -- omi-20210630_lab XML 1.19M
11: EX-101.PRE XBRL Presentations -- omi-20210630_pre XML 745K
7: EX-101.SCH XBRL Schema -- omi-20210630 XSD 113K
71: JSON XBRL Instance as JSON Data -- MetaLinks 355± 492K
72: ZIP XBRL Zipped Folder -- 0000075252-21-000132-xbrl Zip 236K
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. iYes☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). iYes☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “larger accelerated filer”, “accelerated filer”, “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
iAccelerated
filer
☒
Non-accelerated filer
☐ (Do not check if a smaller reporting company)
Smaller reporting company
i☐
Emerging growth company
i☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes i☐ No ☒
The
number of shares of Owens & Minor, Inc.’s common stock outstanding as of July 29, 2021, was i75,462,486 shares.
Note
1—iSummary of Significant Accounting Policies
iBasis
of Presentation
The accompanying unaudited consolidated financial statements include the accounts of Owens & Minor, Inc. and the subsidiaries it controls (we, us, or our) and contain all adjustments (which are comprised only of normal recurring accruals and use of estimates) necessary to conform with U.S. generally accepted accounting principles (GAAP). All significant intercompany accounts and transactions have been eliminated. The Movianto businessrepresented a component that met accounting requirements to be classified as discontinued operations for the three and six months ended June 30, 2020. In accordance with GAAP, the results of operations of the Movianto business are presented as discontinued operations through June
18, 2020 (the Divestiture Date) and, as such, have been excluded from continuing operations for the three and six months ended June 30, 2020. With the exception of Note 3, the Notes to Consolidated Financial Statements reflect the continuing operations of Owens & Minor, Inc. and its subsidiaries. See Note 3 for additional information regarding discontinued operations. The results of operations for interim periods are not necessarily indicative of the results expected for the full year.
i
Reclassifications
Certain
prior year amounts have been reclassified to conform to the current year presentation.
i
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires us to make assumptions and estimates that affect reported amounts and related disclosures. Actual results may differ from these estimates.
iCash,
Cash Equivalents and Restricted Cash
Cash, cash equivalents and restricted cash includes cash and marketable securities with an original maturity or maturity at acquisition of three months or less. Cash, cash equivalents and restricted cash are stated at cost. Nearly all of our cash, cash equivalents and restricted cash are held in cash depository accounts in major banks in the United States, Europe, and Asia. Cash that is held by a major bank and has restrictions on its availability to us is classified as restricted cash. Restricted cash included in Other assets, net as of June 30, 2021 represents cash held in an escrow account as required by the Centers for Medicare & Medicaid Services (CMS) in conjunction with the Bundled Payments for Care Improvement (BPCI) initiatives.
ii
The
following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying consolidated balance sheets that sum to the total of those same amounts presented in the accompanying consolidated statements of cash flows.
iThe carrying amounts of cash and cash equivalents, accounts receivable and accounts payable reported in the consolidated balance sheets approximate fair
value due to the short-term nature of these instruments. The carrying amount of restricted cash also approximates fair value due to its nature. The fair value of debt is estimated based on quoted market prices or dealer quotes for the identical liability when traded as an asset in an active market (Level 1) or, if quoted market prices or dealer quotes are not available, on the borrowing rates currently available for loans with similar terms, credit ratings, and average remaining maturities (Level 2). See Note 6 for the fair value of debt. The fair value of foreign currency contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. See
Note 8 for the fair value of derivatives.
On June 18, 2020, we completed the divestiture of our European logistics business, Movianto (the Divestiture), as well as certain support functions in our Dublin office, to Walden Group SAS (the Buyer) and EHDH (as Buyer’s guarantor) for cash consideration of $i133 million. We concluded that the Movianto business met the criteria for discontinued operations through the
Divestiture Date, as the intention to sell represented a strategic shift and the criteria for held-for-sale were met. Movianto was previously reported in the Global Solutions segment.
Accordingly, the results of operations from the Movianto business are reported in the accompanying consolidated statements of operations as Loss from discontinued operations, net of tax for the three and six months ended June 30, 2020.
i
The
following table summarizes the financial results of our discontinued operations for the three and six months ended June 30, 2020:
Distribution,
selling, and administrative expenses
i76,560
i157,512
Loss
on divestiture
i56,392
i65,472
Acquisition-related
and exit and realignment charges
i4,554
i4,825
Other
operating expenses (income), net
i73
(i388)
Operating
loss
(i54,979)
(i54,585)
Interest
expense, net
i1,424
i3,144
Loss
from discontinued operations before income taxes
(i56,403)
(i57,729)
Income
tax (benefit) provision from discontinued operations
(i615)
i474
Loss
from discontinued operations, net of tax
$
(i55,788)
$
(i58,203)
/
We
suspended depreciation and amortization on assets that are held-for-sale, including right-of-use assets recorded in accordance with ASU No. 2016-02, for the three and six months ended June 30, 2020.
No revenue or expense have been recorded in discontinued operations related to the disposal group subsequent to the Divestiture Date.
We have entered into transition services agreements with a subsidiary of the Buyer, pursuant to which we and a subsidiary of the Buyer will provide to each other various transitional services. Certain transition service arrangement costs and reimbursements were recorded during the three and six months ended June 30, 2021 and were immaterial for the periods presented. These arrangements were substantially completed as of June
30, 2021.
We had iiiino///
assets and liabilities of the discontinued Movianto business reflected on the consolidated balance sheets at June 30, 2021 and December 31, 2020.
The following table provides operating and investing cash flow information for our discontinued operations:
At June 30, 2021, $i55.1 million in net intangible assets were held in the Global Solutions segment and $i166
million were held in the Global Products segment. Amortization expense for intangible assets was $i10.0 million and $i10.6 million for the three months
ended June 30, 2021 and 2020, and $i20.1 million and $i21.2 million
for the six months ended June 30, 2021 and 2020.
Based on the current carrying value of intangible assets subject to amortization, estimated amortization expense is approximately $i20 million for the remainder of 2021, $i39
million for 2022, $i39 million for 2023, $i34 million for
2024, $i28 million for 2025 and $i27 million for 2026.
Note
5—iExit and Realignment Costs
We periodically incur exit and realignment and other charges associated with optimizing our operations which includes the consolidation of certain distribution and outsourced logistics centers, administrative offices and warehouses, our client engagement center and IT restructuring charges. These charges also include costs associated with our strategic organizational realignment which include management changes, certain professional fees,
and costs to streamline administrative functions and processes and divestiture related costs.
i
Exit and realignment charges by segment for the three and six months ended June 30, 2021 and 2020 were as follows:
In addition to the exit and realignment accruals in the preceding table, we also incurred
$i6.2 million and $i10.0 million of costs that were expensed as incurred for the three and six months ended June
30, 2021, which primarily includes $i4.9 million and $i8.0 million related to an increase in reserves associated with certain retained assets of Fusion5 for
the three and six months ended June 30, 2021.
There were iino/
acquisition-related charges included within acquisition-related and exit and realignment charges presented in our consolidated statements of operations for the three and six months ended June 30, 2021. Acquisition-related charges included within acquisition-related and exit and realignment charges presented in our consolidated statements of operations were $i3.9 million and $i8.1 million
for the three and six months ended June 30, 2020 and consisted primarily of transition costs for the Halyard acquisition.
We may incur additional costs in 2021 related to certain retained assets of Fusion5.
We
have $i246 million, excluding debt issuance costs and deferred fees, of i4.375% senior notes due in 2024 (the 2024 Notes), with interest payable semi-annually. The 2024 Notes were sold
at i99.6% of the principal amount with an effective yield of i4.422%. We have the option to redeem the 2024 Notes in part or in whole prior to maturity at a redemption price equal to the greater
of i100% of the principal amount or the present value of the remaining scheduled payments discounted at the applicable Benchmark Treasury Rate (as defined) plus i30
basis points.
In March 2021, we issued $i500 million, excluding debt issuance costs and deferred fees, of i4.500% senior unsecured notes due
in 2029 (the 2029 Unsecured Notes), with interest payable semi-annually (the Notes Offering). The 2029 Unsecured Notes were sold at i100% of the principal amount with an effective yield of i4.500%.
We used a portion of the net proceeds from the Notes Offering to repay our Term B Loan and borrowings under our revolving credit facility. In connection with these repayments, we recorded $i15.3 million in write-offs of deferred financing costs and third party fees within loss on extinguishment of debt for the six months ended June 30, 2021. No write-offs of deferred financing costs and third party fees were recorded for the three months ended June 30,
2021. We may redeem all or part of the 2029 Unsecured Notes prior to March 31, 2024, at a price equal to i100% of the principal amount of the 2029 Unsecured Notes redeemed, plus accrued and unpaid interest, if any, to, but not including, the redemption date, plus a “make-whole” premium, as described in the Indenture dated March 10, 2021 (the Indenture).
On or after March 31, 2024, we may redeem all or part of the 2029 Unsecured Notes at the applicable redemption prices described in the Indenture, plus accrued and unpaid interest, if any, to, but not including, the redemption date. We may also redeem up to i40% of the aggregate principal amount of the 2029 Unsecured Notes at any time prior to March
31, 2024, at a redemption price equal to i104.5% with an amount equal to or less than the net cash proceeds from certain equity offerings, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.
On March 10, 2021, we terminated our then existing credit agreement and all obligations thereunder were repaid. On that same date, we entered into a new credit agreement with Bank of America, N.A. and a syndicate of lenders (the Credit Agreement) with a $i300 million
revolving credit facility. The interest rate on our revolving credit facility is based on a spread over a benchmark rate (as described in the Credit Agreement). The Credit Agreement matures in March 2026.
At June 30, 2021 and December 31, 2020, we had borrowings of $i33.3 million and $i103
million and letters of credit of $i11.4 million and $i13.9 million outstanding under our revolving credit facilities. At June
30, 2021 and December 31, 2020, we had $i255 million and $i283
million available for borrowing. We also had letters of credit and bank guarantees outstanding for $i2.2 million and $i1.6 million as of June
30, 2021 and December 31, 2020, which supports certain leased facilities as well as other normal business activities in the United States and Europe. These letters of credit and guarantees were issued outside of the revolving credit facility.
We entered into a Security and Pledge Agreement (the Security Agreement), dated March 10, 2021, pursuant to which we granted collateral on behalf of the holders of the 2024 Notes, and the parties secured under the Credit Agreement (the Secured Parties) including first priority liens and security interests in (a) all present and future shares of capital stock owned by the Credit Parties (as defined) in the Credit Parties’ present and future subsidiaries, subject to certain customary exceptions,
and (b) all present and future personal property and assets of the Credit Parties, subject to certain exceptions.
On March 10, 2021, we entered into an amendment to our accounts receivable securitization program (the Receivables Securitization Program). Pursuant to the amended Receivables Securitization Program, the aggregate principal amount of the loans made by the Lenders (as defined) will not exceed $i450
million outstanding at any time. The interest rate under the Receivables Securitization Program is based on a spread over a benchmark rate (as described in the Third Amendment to the Receivables Financing Agreement). Under the Receivables Securitization Program, certain of our subsidiaries sell substantially all of their accounts receivable balances to our wholly owned special purpose entity, O&M Funding LLC. The Receivables Securitization Program matures in March 2024.
The Credit Agreement, Receivables Securitization Program, 2024 Notes and 2029 Unsecured Notes contain cross-default provisions which could result in the acceleration of payments due in the event of default of any of the related agreements. The terms of the Credit Agreement also require us to maintain ratios for leverage and interest coverage, including on a pro forma
basis in the event of an acquisition or divestiture. We were in compliance with our debt covenants at June 30, 2021.
As of June 30, 2021, scheduled future principal payments of debt, excluding finance leases and other, were $i476 million in 2024, $i33.3
million in 2026, and $i500 million in 2029. Current maturities at June 30, 2021 include $i1.1 million in current portion of finance leases.
Note
7—iRetirement Plans
We have a noncontributory, unfunded retirement plan for certain retirees in the United States. Certain of our foreign subsidiaries also have defined benefit pension plans covering substantially all of their respective teammates.
iThe
components of net periodic benefit cost for the three and six months ended June 30, 2021 and 2020 were as follows:
We are directly and indirectly affected by changes in foreign currency, which may adversely impact our financial performance and are referred to as “market risks.” When deemed appropriate, we use derivatives as a risk management tool to mitigate the potential impact of certain market risks. We do not enter into derivative financial instruments for trading purposes.
We enter into foreign
currency contracts to manage our foreign exchange exposure related to certain balance sheet items that do not meet the requirements for hedge accounting. These derivative instruments are adjusted to fair value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability.
We determine the fair value of our foreign currency derivatives based on observable market-based inputs or unobservable inputs that are corroborated by market data. We do not view the fair value of our derivatives in isolation, but rather in relation to the fair values or cash flows of the underlying exposure. All derivatives are carried at fair value in our consolidated balance sheets in other current assets and other current liabilities.
We consider the risk of counterparty default to be minimal. We report cash flows from our hedging instruments in the same cash flow statement category as the hedged items.
iThe following table summarizes the terms and fair value of our outstanding derivative financial instruments as of June 30, 2021:
In March 2021, we terminated the remaining $i300 million
in notional value of interest rate swaps concurrent with the debt financing transaction. In September 2020, we terminated $i150 million in notional value of interest rate swaps. The remaining balance of the fair value adjustments of $i25.1 million,
which related to these terminated interest rate swaps, within Accumulated other comprehensive loss was reclassified to Loss on extinguishment of debt within our consolidated statements of operations for the six months ended June 30, 2021.
The following table summarizes the terms and fair value of our outstanding derivative financial instruments as of December 31, 2020:
The
following table summarizes the effect of cash flow hedge accounting on our consolidated statements of operations for the three and six months ended June 30, 2021:
Amount
of Gain Recognized in Other Comprehensive Income (Loss)
Location of Loss Reclassified from Accumulated Other Comprehensive Loss into Income
Total Amount of Expense Line Items Presented in the Consolidated Statement of Operations in Which the Effects are Recorded
Amount of Loss Reclassified from Accumulated Other Comprehensive Loss into Income
The
amount of ineffectiveness associated with these contracts was immaterial for the periods presented.
The following table summarizes the effect of cash flow hedge accounting on our consolidated statements of operations for the three and six months ended June 30, 2020:
The
amount of ineffectiveness associated with these contracts was immaterial for the periods presented.
For the three and six months ended June 30, 2021 we recognized losses of $i0.6 million and $i1.6 million
associated with our economic (non-designated) foreign currency contracts. For the three and six months ended June 30, 2020 we recognized a gain of $i1.3 million and a loss of $i1.4 million
associated with our economic (non-designated) foreign currency contracts.
We recorded the change in fair value of derivative instruments and the remeasurement adjustment of the foreign currency denominated asset or liability in other operating income, net for our foreign exchange contracts.
Note 9—iIncome
Taxes
The effective tax rate was i21.8% and i23.2% for the three and six months ended
June 30, 2021, compared to i96.9% and i28.8% in the same periods of 2020. The change in these rates resulted primarily
from an income tax benefit recorded in the first quarter of 2020 associated with the Coronavirus Aid, Relief, and Economic Security (CARES) Act, the mixture of income and losses in jurisdictions in which we operate, and the incremental income tax benefit associated with the vesting of restricted stock. The liability for unrecognized tax benefits was $i23.6 million at June 30, 2021 and $i20.8 million
at December 31, 2020. Included in the liability at June 30, 2021 and December 31, 2020 were $ii2.7/ million
of tax positions for which ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility.
On August 26, 2020, we received a Notice of Proposed Adjustment (NOPA) from the Internal Revenue Services (IRS) regarding our 2015 and 2016 consolidated income tax returns. On June 30, 2021, we received a NOPA from the IRS regarding our 2017 and 2018 consolidated income tax returns. Within the NOPAs, the IRS has asserted that our taxable income for the aforementioned years should be higher based on their assessment of the appropriate amount of taxable income that we should report in the United States in connection with our sourcing of products by our foreign subsidiaries for sale in the United States
by our domestic subsidiaries. Our amount of taxable income in the United States is based on our transfer pricing methodology, which has been consistently applied through the current date. We strongly disagree with the IRS position and will pursue all available administrative and judicial remedies, including those available under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. We regularly assess the likelihood of adverse outcomes resulting from examinations such as this to determine the adequacy of our tax reserves. We believe that we have adequately reserved for this matter and that the final adjudication of this matter will not have a material impact on our consolidated financial position, results of operations or cash flows. However, the ultimate outcome of disputes of this nature is uncertain, and if the IRS were to prevail on its assertions, the additional
tax, interest, and any potential penalties could have a material adverse impact on our financial position, results of operations or cash flows.
The following summarizes the calculation of net income (loss) per common share attributable to common shareholders for the three and six months ended June 30, 2021 and 2020:
Three
Months Ended June 30,
Six Months Ended June 30,
(in thousands, except per share data)
2021
2020
2021
2020
Income (loss) from continuing operations, net of tax
$
i65,896
$
i161
$
i135,486
$
(i8,748)
Loss
from discontinued operations, net of tax
i—
(i55,788)
i—
(i58,203)
Net
income (loss)
$
i65,896
$
(i55,627)
$
i135,486
$
(i66,951)
Weighted
average shares outstanding - basic
i72,818
i61,128
i72,474
i60,819
Dilutive
shares
i2,987
i—
i2,791
i—
Weighted
average shares outstanding - diluted
i75,805
i61,128
i75,265
i60,819
Basic
income (loss) per common share:
Income (loss) from continuing operations
$
i0.90
$
i—
$
i1.87
$
(i0.14)
Loss
from discontinued operations
i—
(i0.91)
i—
(i0.96)
Net
income (loss)
$
i0.90
$
(i0.91)
$
i1.87
$
(i1.10)
Diluted
income (loss) per common share:
Income (loss) from continuing operations
$
i0.87
$
i—
$
i1.80
$
(i0.14)
Loss
from discontinued operations
i—
(i0.91)
i—
(i0.96)
Net
income (loss)
$
i0.87
$
(i0.91)
$
i1.80
$
(i1.10)
/
Note
11—iShareholders' Equity
In May 2020, we entered into an equity distribution agreement, pursuant to which we may offer and sell, from time to time, shares of our common stock having an aggregate offering price of up to $i50.0 million.
We intend to use the net proceeds from the sale of our securities offered by this program for the repayment of indebtedness and/or for general corporate and working capital purposes. As of June 30, 2021, ino shares were issued and $i50.0 million
of common stock remained available under the at-the-market equity financing program.
Note 12—iAccumulated Other Comprehensive Loss
iThe
following table shows the changes in accumulated other comprehensive loss by component for the three and six months ended June 30, 2021 and 2020:
We
include amounts reclassified out of accumulated other comprehensive loss related to defined benefit pension plans as a component of net periodic pension cost recorded in Other expense, net.
Note 13—iSegment Information
i
We
periodically evaluate our application of accounting guidance for reportable segments and disclose information about reportable segments based on the way management organizes the enterprise for making operating decisions and assessing performance. We report our business under itwo segments: Global Solutions and Global Products. The Global Solutions segment includes our United States distribution businesses (Medical Distribution and Patient Direct), outsourced logistics and value-added services business. Global Products manufactures and sources medical surgical
products through our production and kitting operations.
We evaluate the performance of our segments based on their operating income excluding intangible amortization and acquisition-related and exit and realignment charges that, either as a result of their nature or size, would not be expected to occur as part of our normal business operations on a regular basis.
/
Segment assets exclude inter-segment account balances as we believe their inclusion would be misleading and not meaningful. We believe all inter-segment sales are at prices that approximate market.
iThe
following tables present financial information by segment:
iThe
following table presents net revenue by geographic area, which were attributed based on the location from which we ship products or provide services.
In
December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We adopted ASU No. 2019-12 effective beginning January 1, 2021. Its adoption did not have a material impact on our consolidated financial statements.
In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional expedients and exceptions for applying GAAP to contracts,
hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of March 12, 2020 through December 31, 2022. Our current debt agreements contemplate a transition from LIBOR to another benchmark rate in the event that LIBOR ceases to exist. We do not expect the transition to have a material impact on our consolidated financial statements.
In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements, to improve consistency by amending the FASB
Accounting Standards Codification (the Codification) to include all disclosure guidance in the appropriate disclosure sections. This ASU also clarifies application of various provisions in the Codification by amending and adding new headings, cross referencing to other guidance, and refining or correcting terminology. The amendments in this ASU do not change GAAP and, therefore, are not expected to result in a significant change in practice. We adopted ASU No. 2020-10 effective beginning January 1, 2021. Its adoption did not have a material impact on our consolidated financial statements.
There have been no further changes in our significant accounting policies from those contained in our Annual Report on Form 10-K for the year ended December 31, 2020.
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis describes results of operations and material changes in the financial condition of Owens & Minor, Inc. and its subsidiaries since December 31, 2020. Trends of a material nature are discussed to the extent known and considered relevant. This discussion should be read in conjunction with the consolidated financial statements, related notes thereto, and management’s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December 31, 2020.
Overview
Owens
& Minor, Inc., along with its subsidiaries, (we, us, or our) is a leading global healthcare solutions company. On June 18, 2020 (the Divestiture Date), we completed the divestiture of our European logistics business, Movianto (the Divestiture), as well as certain support functions in our Dublin, Ireland office, to Walden Group SAS (the Buyer) and EHDH (as Buyer’s guarantor) for cash consideration of $133 million. The Divestiture provides us with a greater ability to focus on and invest in our differentiated products, services and U.S. distribution businesses.
As a result of the Divestiture, the results of operations from our Movianto business are reported as “Loss from discontinued operations, net of tax” for the three and six months ended June
30, 2020. See Note 3, “Discontinued Operations,” of the Notes to Consolidated Financial Statements for further information. Unless otherwise indicated, the following information relates to continuing operations.
Income from continuing operations per diluted share was $0.87 and $1.80 for the three and six months ended June 30, 2021 as compared to $0.00 and $(0.14) for the three and six months ended June 30, 2020. Global Solutions segment operating income (loss) was $18.5 million and $27.4 million for the three and six months ended June 30, 2021, compared to $(10.1) million and $(2.5) million for the three and six months ended June 30, 2020. The increase was a result of higher volumes
coupled with productivity and efficiency gains in our Medical Distribution business compared to the prior year. Global Products segment operating income was $95.3 million and $259 million for the three and six months ended June 30, 2021, compared to $51.8 millon and $70.3 million for the three and six months ended June 30, 2020. The increase was a result of higher personal protective equipment (PPE) sales, favorable timing of cost pass-through on gloves, productivity initiatives, favorable product mix, and improved fixed cost leverage, partially offset by higher commodity prices and elevated transportation costs, compared to the prior year.
COVID-19 Update
We are closely
monitoring the impact of the 2019 novel coronavirus (COVID-19) on all aspects of our business, including how it impacts our customers, teammates, suppliers, vendors and distribution channels. We have taken actions to protect our teammates while maintaining business continuity as we respond to the needs from this global pandemic. We will continue to actively monitor the situation and may take further actions that alter our business operations as may be required by federal, state or local authorities or that we determine are in the best interests of our teammates, customers, suppliers and shareholders.
Revenue for the three and six months ended June 30, 2021 of $2.5 billion and $4.8 billion continues to be impacted by COVID-19 and includes the effective response to the ongoing recovery of elective procedures, higher sales of PPE, and pass-through of elevated glove costs. Operating
income also benefited from improved productivity and increased manufacturing output related to PPE, favorable product mix and operating efficiencies. We have expanded our PPE production operations and have taken measures to increase and improve our production such as retooling existing equipment, installing and optimizing new production lines and ramping up our new non-woven fabric machinery. We expect that we will continue servicing our customers' needs related to the heightened demand for our PPE as a result of various factors, including the implementation of new regulations and healthcare protocols calling for increased use of PPE, healthcare professional preference for medical grade PPE, stockpile PPE demand and the creation of new channels for PPE demand in healthcare, non-healthcare and international markets.
In March 2020, under the Defense Production Act (DPA), we were awarded a contract
with the U.S. Department of Health and Human Services to produce N-95 respirator masks in an effort to replenish the Strategic National Stockpile. In April 2020, also under the DPA, the U.S. Department of Defense initiated a technology investment agreement with us involving up to $30.0 million of anticipated funding of assets to expand capacity to supply N-95 respirator masks. Through June 30, 2021, substantially all of the anticipated funding had been expended and reimbursed in accordance with this arrangement.
We are unable to predict the timing of the pandemic and the full impact that COVID-19 will have on our future operating results, financial position and cash flows due to numerous variables and continued uncertainties. Travel, transportation, and business operation restrictions arising from virus containment efforts of governments around the world have continued to impact
our operations in certain locations, including within Asia. Essential activity exceptions from these restrictions have allowed us to continue to operate but virus containment efforts have resulted in additional direct costs from supply chain challenges. Although we have experienced growth in sales volumes for certain of our products (such as PPE) during the COVID-19 pandemic, as well as improved productivity and manufacturing output, there can be no assurance that such growth rates, increased sales volumes or other improvements will be maintained during or following the COVID-19 pandemic.
The change in net revenue for the three and six months ended June 30, 2021 reflected the effective response to the ongoing recovery of elective procedures, higher sales of PPE, pass-through of elevated glove costs, as well as continued strong performance
in our Patient Direct business. Foreign currency translation had a favorable impact on net revenue of $12.3 million and $21.7 million for the three and six months ended June 30, 2021 as compared to the prior year.
Cost of goods sold.
Three
Months Ended June 30,
Change
(Dollars in thousands)
2021
2020
$
%
Cost of goods sold
$
2,089,392
$
1,538,312
$
551,080
35.8
%
Six
Months Ended June 30,
Change
(Dollars in thousands)
2021
2020
$
%
Cost of goods sold
$
3,973,175
$
3,392,445
$
580,730
17.1
%
Cost
of goods sold includes the cost of the product (net of supplier incentives and cash discounts) and all costs incurred for shipments of products from manufacturers to our distribution centers for all customer arrangements where we are the primary obligor and bear risk of general and physical inventory loss. These are sometimes referred to as distribution contracts. Cost of goods sold also includes direct and certain indirect labor, material and overhead costs associated with our Global Products segment. There is no cost of goods sold associated with our fee-for-service arrangements. Cost of goods sold compared to prior year reflects changes in sales activity, including sales mix.
Gross margin.
Three
Months Ended June 30,
Change
(Dollars in thousands)
2021
2020
$
%
Gross margin
$
400,068
$
269,407
$
130,661
48.5
%
As
a % of net revenue
16.07
%
14.90
%
Six
Months Ended June 30,
Change
(Dollars in thousands)
2021
2020
$
%
Gross margin
$
842,819
$
537,967
$
304,852
56.7
%
As
a % of net revenue
17.50
%
13.69
%
Gross margin increase in the three and six months ended June 30, 2021 was driven by revenue growth, market dynamics including timing of glove price and cost changes, an overall improved sales mix and operating efficiencies, partially offset by higher commodity prices and transportation costs in our Global Products segment. Foreign currency translation had an unfavorable impact on gross margin of $0.8 million for the three months ended June
30, 2021 and a favorable impact on gross margin of $5.4 million for the six months ended June 30, 2021, as compared to the prior year.
Acquisition-related and exit and realignment charges
$
8,624
$
6,054
$
2,570
42.5
%
Other
operating expense (income), net
$
464
$
(577)
$
1,041
180.4
%
Six
Months Ended June 30,
Change
(Dollars in thousands)
2021
2020
$
%
Distribution, selling and administrative expenses
$
586,796
$
495,782
$
91,014
18.4
%
As
a % of net revenue
12.18
%
12.61
%
Acquisition-related and exit and realignment charges
$
14,587
$
12,118
$
2,469
20.4
%
Other
operating expense (income), net
$
(2,141)
$
(2,886)
$
745
25.8
%
Distribution, selling and administrative (DS&A) expenses include labor and warehousing costs associated with our distribution and outsourced logistics services and all costs associated with our fee-for-service arrangements. Shipping and handling costs are primarily included in DS&A expenses and include
costs to store, move, and prepare products for shipment, as well as costs to deliver products to customers. Overall DS&A expenses were affected by revenue growth, increase in incentive compensation, and teammate benefits, partially offset by operational efficiencies for the three and six months ended June 30, 2021. In addition, overall DS&A expenses were affected by charitable contributions for the six months ended June 30, 2021. DS&A expenses also included an unfavorable impact for foreign currency translation of $1.2 million and $2.2 million for the three and six months ended June 30, 2021.
There were no acquisition-related charges for the three and six months ended June 30, 2021 compared to $3.9 million and $8.1
million for the same periods of 2020, which consisted primarily of transition costs for the Halyard acquisition. Exit and realignment charges were $8.6million and $14.6million for the three and six months ended June 30, 2021 and consisted primarily of an increase in reserves associated with certain retained assets of Fusion5, IT restructuring charges and other costs related to the reorganization of the U.S. operations. Exit and realignment charges were $2.2 million and $4.0 million for the three and six months ended June 30, 2020 and consisted primarily of severance from reduction in force and other costs related to the reorganization of the U.S. commercial, operations and executive teams.
The change in other operating income, net
for the three months ended June 30, 2020 was attributed primarily to foreign currency transaction gains as compared to losses in the prior year and losses from the adjustments to fair value on our foreign currency contracts compared to gains in the prior year. The change in other operating income, net for the six months ended June 30, 2020 was attributed primarily to lower foreign currency transaction gains compared to prior year.
Interest expense, net and the effective interest rate for the three and six months ended June
30, 2021 decreased primarily due to a reduction of debt and lower interest rates. See Note 6 in Notes to Consolidated Financial Statements.
(Gain) loss on extinguishment of debt.
Three Months Ended June 30,
Change
(Dollars
in thousands)
2021
2020
$
%
(Gain) loss on extinguishment of debt
$
—
$
(1,856)
$
1,856
100.0
%
Six
Months Ended June 30,
Change
(Dollars in thousands)
2021
2020
$
%
(Gain) loss on extinguishment of debt
$
40,433
$
2,271
$
38,162
1,680.4
%
Loss
on extinguishment of debt for the six months ended June 30, 2021 includes the write-off of deferred financing costs and third party fees associated with the debt financing in March 2021 of $15.3 million and amounts reclassified from accumulated other comprehensive loss as a result of the termination of our interest rate swaps of $25.1 million. (Gain) loss on extinguishment of debt for the three and six months ended June 30, 2020 primarily includes the write-off of deferred financing costs and third party fees, offset by the gain on extinguishment of debt related to the partial repurchase of our 2021 and 2024 Notes.
Other expense (income), net.
Three
Months Ended June 30,
Change
(Dollars in thousands)
2021
2020
$
%
Other expense (income), net
$
1,028
$
(2,696)
$
3,724
138.1
%
Six
Months Ended June 30,
Change
(Dollars in thousands)
2021
2020
$
%
Other expense (income), net
$
1,598
$
(1,977)
$
3,575
180.8
%
Other
expense (income), net for the three and six months ended June 30, 2021 represents interest cost and net actuarial losses related to our retirement plans. Other expense (income), net for the three and six months ended June 30, 2020 includes a gain from the surrender of company-owned life insurance policies interest cost and net actuarial losses related to our retirement plans.
The change in the effective tax rate for the three and six months ended June 30, 2021 compared to the same periods in 2020 resulted primarily from an income
tax benefit recorded in the first quarter of 2020 associated with the Coronavirus Aid, Relief, and Economic Security (CARES) Act, the mixture of income and losses in jurisdictions in which we operate, and the incremental income tax benefit associated with the vesting of restricted stock.
Financial Condition, Liquidity and Capital Resources
Financial condition. We monitor operating working capital through days sales outstanding (DSO) and merchandise inventory days. We estimate a hypothetical increase (decrease) in DSO of one day would result in a decrease (increase) in our cash balances, an increase (decrease) in borrowings against our revolving credit facility or Receivables Securitization Program, or a combination thereof of approximately $27 million.
The
majority of our cash and cash equivalents are held in cash depository accounts with major banks in the United States, Europe, and Asia. Changes in our working capital can vary in the normal course of business based upon the timing of inventory purchases, collections of accounts receivable, and payments to suppliers.
(2) Based on period end merchandise inventories and cost of goods sold for the
quarters ended June 30, 2021 and December 31, 2020
Liquidity and capital expenditures. The following table summarizes our consolidated statements of cash flows for the six months ended June 30, 2021 and 2020, which relates to continuing operations and discontinued operations:
(Dollars in thousands)
2021
2020
Net
cash provided by (used for):
Operating activities
$
12,406
$
150,457
Investing activities
(18,659)
126,959
Financing activities
(64,788)
(171,062)
Effect
of exchange rate changes
(1,718)
5,412
Net (decrease) increase in cash, cash equivalents and restricted cash
$
(72,759)
$
111,766
Cash provided by operating activities in the first six months of 2021 and 2020 reflected fluctuations in net income along with changes in working capital.
Cash used for investing activities
in the first six months of 2021 and 2020 included capital expenditures of $18.7 million and $12.1 million for our strategic and operational efficiency initiatives associated with property and equipment, investments for increased manufacturing capacity in the Americas, and capitalized software. Cash provided by investing activities in the first six months of 2020 also included cash consideration received of $133 million from the sale of Movianto and proceeds of $6.0 million from the surrender of company-owned life insurance policies.
Cash
used for financing activities in the first six months of 2021 included dividend payments of $0.4 million and repayments of $69.9 million under our revolving credit facility, compared to $0.3 million and $47.9 million for the same period of 2020. We also had proceeds from borrowings of $575 million related to the 2029 Unsecured Notes and Accounts Receivable Securitization Program for the first six months of 2021, compared to $150 million related to the Accounts Receivable Securitization Program for the first six months of 2020. Financing activities also included repayments of $523 million for the first six months of 2021 compared to $258 million in the same period of 2020 on our term loans and 2021 and 2024 Notes. We used $83.2 million of cash to repurchase $87.8 million aggregate principal amount of the 2021
and 2024 Notes during the first six months of 2020. We also paid $12.9 million in financing costs, as compared to $10.4 million in financing costs for the same period of 2020. In addition, we paid $15.4 million to terminate the remaining $300 million in notional value of interest rate swaps during the first six months of 2021. Payments for taxes related to the vesting of restricted stock awards were $19.1 million and $3.1 million for the first six months of 2021 and 2020, which are included in Other, net.
Capital resources. Our sources of liquidity include cash and cash equivalents, a revolving credit facility under our Credit Agreement with Bank of America, N.A, as an administrative agent and collateral agent, and a syndicate of financial institutions, as lenders (the Credit Agreement), and the Receivables Securitization
Program. The Credit Agreement provides a revolving borrowing capacity of $300 million. The interest rate on our revolving credit facility is based on a spread over a benchmark rate (as described in the Credit Agreement). The Credit Agreement matures in March 2026.
At June 30, 2021 and December 31, 2020, we had borrowings of $33.3 million and $103 million, and letters of credit of $11.4 million and $13.9 million outstanding under our credit agreements. At June 30, 2021 and December 31, 2020, we had $255 million and $283 million, available for borrowing. We also had letters of credit and bank guarantees outstanding for $2.2 million and $1.6 million as of June
30, 2021 and December 31, 2020, which supports certain leased facilities as well as other normal business activities in the United States and Europe. These letters of credit and guarantees were issued outside of the revolving credit facility.
We entered into a Security and Pledge Agreement (the Security Agreement), dated March 10, 2021, pursuant to which we granted collateral on behalf of the holders of the 2024 Notes, and the parties secured under the Credit Agreement (the Secured Parties) including first priority liens and security interests in (a) all present and future shares of capital stock owned by the Credit Parties (as defined) in the Credit Parties’ present and future subsidiaries, subject to certain customary exceptions,
and (b) all present and future personal property and assets of the Credit Parties, subject to certain exceptions.
On March 10, 2021, we entered into an amendment to our accounts receivable securitization program (the Receivables Securitization Program). Pursuant to the amended Receivables Securitization Program, the aggregate principal amount of the loans made by the Lenders (as defined) will not exceed $450 million outstanding at any time. The interest rate under the Receivables Securitization Program is based on a spread over a benchmark rate (as described in the Third Amendment to the Receivables Financing Agreement). Under the Receivables Securitization Program, certain of our subsidiaries sell substantially all of their accounts receivable balances to our wholly owned special purpose
entity, O&M Funding LLC. The Receivables Securitization Program matures in March 2024.
The Credit Agreement, Receivables Securitization Program, 2024 Notes and 2029 Unsecured Notes contain cross-default provisions which could result in the acceleration of payments due in the event of default of any of the related agreements. The terms of the Credit Agreement also require us to maintain ratios for leverage and interest coverage, including on a pro forma basis in the event of an acquisition or divestiture. We were in compliance with our debt covenants at June 30, 2021.
In May 2020, we entered into an equity distribution agreement, pursuant to which we may offer and sell, from time to time, shares of our common stock having an aggregate offering price of up to $50.0 million. We intend to use the net proceeds from the sale of our
securities offered by this program for the repayment of indebtedness and/or for general corporate and working capital purposes. As of June 30, 2021 no shares were issued and $50.0 million of common stock remained available under the at-the-market equity financing program.
We regularly evaluate market conditions, our liquidity profile and various financing alternatives to enhance our capital structure. From time to time, we may enter into transactions to repay, repurchase or redeem our outstanding indebtedness (including by means of open market purchases, privately negotiated repurchases, tender or exchange offers and/or repayments or redemptions pursuant to the debt’s terms). Our ability to consummate any such transaction will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. We cannot provide any assurance as to
if or when we will consummate any such transactions or the terms of any such transaction.
The second quarter dividend of $0.0025 per share was paid in June 2021. The payment of future dividends remains within the discretion of the Board of Directors and will depend upon our results of operations, financial condition, capital requirements, current and future limitations under our Credit Agreement and other factors.
We believe available financing sources, including cash generated by operating activities and borrowings under the Credit Agreement and Receivables Securitization
Program, will be sufficient to fund our working capital needs, capital expenditures, long-term strategic growth, payments under long-term debt and lease arrangements, payments of quarterly cash dividends, debt repurchases and other cash requirements. While we believe that we will have the ability to meet our financing needs in the foreseeable future, changes in economic conditions may impact (i) the ability of financial institutions to meet their contractual commitments to us, (ii) the ability of our customers and suppliers to meet their obligations to us or (iii) our cost of borrowing.
We earn a portion of our operating income in foreign jurisdictions outside the United States. Our cash and cash equivalents held by our foreign subsidiaries totaled $28.9 million and $72.0 million at June 30,
2021 and December 31, 2020. We continue to remain permanently reinvested in our foreign subsidiaries, with the exception of a subsidiary in Thailand. We have no specific plans to indefinitely reinvest the unremitted earnings of our foreign subsidiary located in Thailand as of June 30, 2021. As such, we have recorded withholding tax liabilities that would be incurred upon future distribution to the U.S. There are no unrecognized deferred taxes as there is no outside basis difference unrelated to unremitted earnings for Thailand. We will continue to evaluate our foreign earnings repatriation policy in 2021 for all our foreign subsidiaries.
Guarantor
and Collateral Group Summarized Financial Information
We are providing the following information in compliance with Rule 13-01, “Financial Disclosures about Guarantors and Issuers of Guaranteed Securities” and Rule 13-02 of Regulation S-X, of with respect to our 2024 Notes. See Note 6 of the accompanying consolidated financial statements for additional information regarding the terms of the 2024 Notes.
The following tables present summarized financial information for Owens & Minor, Inc. and the guarantors of Owens & Minor, Inc.’s 2024 Notes (together, "the Guarantor Group"), on a combined basis with intercompany balances and transactions between entities in the Guarantor Group eliminated. The guarantor subsidiaries are 100% owned by Owens &
Minor, Inc. Separate financial statements of the guarantor subsidiaries are not presented because the guarantees by our guarantor subsidiaries are full and unconditional, as well as joint and several.
Summarized financial information of the Guarantor Group is as follows:
Summarized Consolidated Statement of Operations - Guarantor Group
The
following tables present summarized financial information for Owens & Minor, Inc. and the subsidiaries of Owens & Minor, Inc.’s 2024 Notes pledged that constitute a substantial portion of collateral (together, "the Collateral Group"), on a combined basis with intercompany balances and transactions between entities in the Collateral Group eliminated. The pledged subsidiaries are 100% owned by Owens & Minor, Inc. No trading market for the subsidiaries included in the Collateral Group exists.
Summarized financial information of the Collateral Group is as follows:
The results of operations of the Collateral Group are not materially different from the corresponding amounts presented in our consolidated statements of operations.
Recent Accounting Pronouncements
For a discussion of recent accounting pronouncements, see our Annual
Report on Form 10-K for the year ended December 31, 2020 and Note 14 in the Notes to Consolidated Financial Statements, included in this Quarterly Report on Form 10-Q for the period ended on June 30, 2021.
Forward-looking Statements
Certain statements in this discussion constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Although we believe our expectations with respect to the forward-looking statements are based upon reasonable assumptions within the bounds of our knowledge of our business and operations, all forward-looking statements involve risks and uncertainties and, as a result, actual results could differ materially from those projected, anticipated
or implied by these statements. Such forward-looking statements involve known and unknown risks, including, but not limited to:
•our ability to achieve revenue and operating income goals may be affected by: COVID-19 related factors, risks and challenges, including among others, the length of time that the pandemic continues, and any worsening of the pandemic, including through any new variant strains of the underlying virus, or future pandemics, related governmental responses, the effectiveness, availability, and public acceptance of vaccines, a decrease in revenue ultimately resulting in less cash flow, longer duration in receivables collection, the need to expedite payments to important suppliers may grow, shifts in demand away from certain products we manufacture and distribute, reduced workforces which may be caused by, but not limited to, the temporary inability of the workforce to work due to illness,
quarantine, or government mandates, temporary production and distribution center and office closures due to reduced workforces or government mandates, availability of raw materials, potential resulting labor negotiations or disputes, changes in the types and numbers of businesses that compete with us, including non-traditional competitors, and the aggressiveness of that competition, impacts of the pandemic or future pandemics on other third parties with whom we conduct business, the healthcare industry, and the broader business environment, and trends in elective surgeries and other healthcare spending not directly associated with COVID-19;
•competitive pressures in the marketplace, including intense pricing pressure;
•our ability to retain existing and attract new customers in a market characterized by significant customer consolidation
and intense cost-containment initiatives;
•our dependence on sales to certain customers or the loss or material reduction in purchases by key customers;
•our dependence on distribution of product of certain suppliers;
•our ability to successfully identify, manage or integrate acquisitions;
•our ability to successfully manage our international operations, including risks associated with changes in international trade regulations, foreign currency volatility, changes in regulatory conditions, deteriorating economic conditions, adverse tax consequences, and other risks of operating in international markets;
•uncertainties related to and
our ability to adapt to changes in government regulations, including healthcare laws and regulations;
•risks arising from possible violations of legal, regulatory or licensing requirements of the markets in which we operate;
•uncertainties related to general economic, regulatory and business conditions;
•our ability to successfully implement our strategic initiatives;
•the availability
of and modifications to existing supplier funding programs and our ability to meet the terms to qualify for certain of these programs;
•the effect of price volatility in the commodities markets, including fuel price fluctuations, on our operating costs and supplier product prices;
•our ability to adapt to changes in product pricing and other terms of purchase by suppliers of product;
•the ability of customers and suppliers to meet financial commitments due to us;
•changes in manufacturer preferences between direct sales and wholesale distribution;
•changing trends in customer profiles and ordering patterns and our ability to meet customer
demand for additional value-added services;
•our ability to manage operating expenses and improve operational efficiencies in response to changing customer profiles;
•our ability to meet performance targets specified by customer contracts under contractual commitments;
•availability of and our ability to access special inventory buying opportunities;
•the ability of business partners and financial institutions to perform their contractual responsibilities;
•our ability to continue to obtain financing, obtain financing at reasonable rates and to
manage financing costs and interest rate risk, and our ability to refinance, extend or repay our substantial indebtedness;
•the risk that information systems are interrupted or damaged or fail for any extended period of time, that new information systems are not successfully implemented or integrated, or that there is a data security breach in our information systems;
•the risk that a decline in business volume or profitability could result in an impairment of goodwill or other long-lived assets;
•our ability to timely or adequately respond to technological advances in the medical supply industry;
•the costs associated with and outcome of outstanding and any future litigation, including product and professional
liability claims;
•adverse changes in U.S. and foreign tax laws and the outcome of outstanding tax contingencies and legislative and tax proposals;
•our ability to successfully implement the expense reduction and productivity and efficiency initiatives;
•our ability to continue to comply with the terms and conditions of Byram Healthcare’s Corporate Integrity Agreement; and
•other factors detailed from time to time in the reports we file with the SEC, including those described in “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2020.
We undertake no obligation to
update or revise any forward-looking statements, except as required by applicable law.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are subject to price risk for our raw materials, the most significant of which relates to the cost of polypropylene and nitrile used in the manufacturing processes of our Global Products segment. Prices of the commodities underlying these raw materials are volatile and have fluctuated significantly in recent years and in the future may contribute to fluctuations in our results of operations. The ability to hedge these commodity prices is limited.
In the normal course of business, we are
exposed to foreign currency translation and transaction risks. Our business transactions outside of the United States are denominated in the euro, Malaysian ringgit, Mexican peso, Thai baht and other currencies. We may use foreign currency forwards, swaps and options, where possible, to manage our risk related to certain foreign currency fluctuations.
We are exposed to market risk from changes in interest rates related to our borrowing under our Credit Agreement and Receivables Securitization Program. We had $33.3 million in borrowings under our revolving credit facility, $226 million
in borrowings under our Receivables Securitization Program and $11.4 million in letters of credit under the Credit Agreement at June 30, 2021. We estimate an increase in interest rates of 100 basis points would result in a potential reduction in future pre-tax earnings of approximately $2.7 million per year based on our borrowings outstanding at June 30, 2021.
Due to the nature and pricing of our Global Solutions segment distribution services, we are exposed to potential volatility in fuel prices. Our strategies for helping to mitigate our exposure to changing domestic fuel prices have included using trucks with improved fuel efficiency. We benchmark our domestic diesel fuel purchase prices against the U.S. Weekly Retail On-Highway Diesel Prices (benchmark) as quoted by the U.S. Energy Information Administration. The benchmark
averaged $3.06 and $2.66 per gallon in the first six months of 2021 and 2020. Based on our fuel consumption in the first six months of 2021, we estimate that every 10 cents per gallon increase in the benchmark would reduce our Global Solutions segment operating income by approximately $0.2 million on an annualized basis.
Item 4. Controls and Procedures
We carried out an evaluation, with the participation of management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (pursuant to Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based upon that evaluation,
the principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of June 30, 2021. There was no change in our internal control over financial reporting that occurred during the period of this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Part II. Other Information
Item 1. Legal Proceedings
Certain legal proceedings pending
against us are described in our Annual Report on Form 10-K for the year ended December 31, 2020. Through June 30, 2021, there have been no material developments in any legal proceedings reported in such Annual Report.
Item 1A. Risk Factors
Certain risk factors that we believe could affect our business and prospects are described in our Annual Report on Form 10-K for the year ended December 31, 2020. Through June 30, 2021, we have added the following risk factor. There have been no other material changes in the risk
factors described in such Annual Report.
Our operations depend on the proper functioning of information systems, and our business or results of operations could be adversely affected if we experience a cyberattack or other systems breach or failure.
We and our external service providers use and rely on information systems to perform our business operations including receiving, processing, analyzing, and managing data in distributing thousands of products to customers from numerous distribution centers. These systems are also relied upon for receiving and filling orders for customers, billings to and collections from customers, the purchase of and payment for inventory and related transactions from our suppliers, and the secure electronic transmission, processing, storage, and hosting of sensitive information, including protected health information and
other types of personal information, confidential financial information, proprietary information, and other sensitive information relating to our customers, company, and teammates.
Despite physical, technical, and administrative security measures, our technology systems and operations may be subject to cyberattacks from sources beyond our control. In recent months, cyberattacks in our industry have increased and become more sophisticated and, as a result, the risk of a cyberattack on our systems has increased. Cyberattacks include actual or attempted unauthorized access, tampering, malware insertion, ransomware attacks, or other system integrity events. A cybersecurity incident could involve a material data breach or other material impact to the operations of our technology systems, which could result in failure of our systems to operate properly for an extended period of time, litigation or regulatory action, loss of customers
or revenue, and increased expense, any of which might have a material adverse impact on our business operations, reputation, and our financial position or results of operations.
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities
In May 2020, we entered into an equity distribution agreement, pursuant to which we may offer and sell, from time
to time, shares of our common stock having an aggregate offering price of up to $50.0 million. We intend to use the net proceeds from the sale of our securities offered by this program for the repayment of indebtedness and/or for general corporate and working capital purposes. As of June 30, 2021, no shares were issued and $50.0 million of common stock remained available under the at-the-market equity financing program.
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
